Chunmeng Wang

2.2k total citations
32 papers, 1.6k citations indexed

About

Chunmeng Wang is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Chunmeng Wang has authored 32 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 10 papers in Immunology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Chunmeng Wang's work include CAR-T cell therapy research (17 papers), Lymphoma Diagnosis and Treatment (9 papers) and Immune Cell Function and Interaction (7 papers). Chunmeng Wang is often cited by papers focused on CAR-T cell therapy research (17 papers), Lymphoma Diagnosis and Treatment (9 papers) and Immune Cell Function and Interaction (7 papers). Chunmeng Wang collaborates with scholars based in China, United States and Russia. Chunmeng Wang's co-authors include Weidong Han, Qingming Yang, Yao Wang, Yelei Guo, Meixia Chen, Yang Liu, Wenying Zhang, Hanren Dai, Zhiqiang Wu and Chuan Tong and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Chunmeng Wang

29 papers receiving 1.6k citations

Peers

Chunmeng Wang
Reed M. Hawkins United States
Sherry Adkins United States
Jinjuan Wang China
Oumar Diouf United States
Xiaojun Qian China
Kathryn M. Cappell United States
Brandon Ballard United States
Nicholas Tschernia United States
Yongxian Hu China
Maria‐Luisa Schubert Germany
Reed M. Hawkins United States
Chunmeng Wang
Citations per year, relative to Chunmeng Wang Chunmeng Wang (= 1×) peers Reed M. Hawkins

Countries citing papers authored by Chunmeng Wang

Since Specialization
Citations

This map shows the geographic impact of Chunmeng Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chunmeng Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chunmeng Wang more than expected).

Fields of papers citing papers by Chunmeng Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chunmeng Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chunmeng Wang. The network helps show where Chunmeng Wang may publish in the future.

Co-authorship network of co-authors of Chunmeng Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Chunmeng Wang. A scholar is included among the top collaborators of Chunmeng Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chunmeng Wang. Chunmeng Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wei, Jian‐Jun, et al.. (2025). Comparison between arm port and chest port: A systematic review and meta-analysis. The Journal of Vascular Access. 26(6). 1814–1828.
2.
Wang, Tiance, Jiejie Liu, Yan Zhang, et al.. (2025). Manganese mediates nucleoplasm distribution of cGAS to enhance systemic antitumor immunity and drive abscopal effect. Cancer Letters. 637. 218154–218154.
3.
Liu, Yang, Qingming Yang, Chunmeng Wang, et al.. (2024). The interim analysis of a first-in-human phase 1 trial of ET-901, a CRISPR edited allogeneic immune-cloaked anti-CD19 CAR-T cell therapy in patients with r/r B-NHL.. Journal of Clinical Oncology. 42(16_suppl). e19010–e19010. 2 indexed citations
4.
Yang, Yuzhuo, Xin Lin, Yao Wang, et al.. (2023). IL-6 translation is a therapeutic target of human cytokine release syndrome. The Journal of Experimental Medicine. 220(11). 14 indexed citations
5.
Wang, Yao, Chuan Tong, Yuting Lu, et al.. (2023). Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma. Signal Transduction and Targeted Therapy. 8(1). 409–409. 35 indexed citations
6.
Li, Xiang, Yaru Li, Liang Dong, et al.. (2023). Decitabine priming increases anti–PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models. Journal of Clinical Investigation. 133(7). 47 indexed citations
7.
Liu, Zongzhi, Yibo Gao, Jiejie Liu, et al.. (2023). Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy. Molecular Cancer. 22(1). 84–84. 31 indexed citations
8.
Zhang, Xiaoyi, Chunmeng Wang, Z. Y. Zhou, & Qi Zhang. (2023). The mitochondrial‐endoplasmic reticulum co‐transfer in dental pulp stromal cell promotes pulp injury repair. Cell Proliferation. 57(1). e13530–e13530. 8 indexed citations
9.
Wang, Chunmeng, Yang Liu, Guanghua Rong, et al.. (2023). Long‐term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine‐plus‐camrelizumab epi‐immunotherapy and treatment cessation. SHILAP Revista de lepidopterología. 4(6). e428–e428. 2 indexed citations
10.
Li, Wen, Cheng Zhang, Jingying Liu, et al.. (2022). Design, synthesis, and anticancer evaluation of ammosamide B with pyrroloquinoline derivatives as novel BRD4 inhibitors. Bioorganic Chemistry. 127. 105917–105917. 7 indexed citations
11.
Wang, Chunmeng, Yang Liu, Liang Dong, et al.. (2021). Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy. Clinical Cancer Research. 27(10). 2782–2791. 29 indexed citations
12.
Wang, Yao, Yang Liu, Chuan Tong, et al.. (2021). Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial. Leukemia. 36(1). 189–196. 64 indexed citations
13.
Wang, Chunmeng, Fengxia Shi, Yang Liu, et al.. (2021). Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. Journal of Hematology & Oncology. 14(1). 1 indexed citations
14.
Li, Xiang, Liang Dong, Jiejie Liu, et al.. (2021). Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ+ CD4+ T Cells Through Enhancing IκBα Degradation and NF-κB Activation. Frontiers in Cell and Developmental Biology. 9. 647713–647713. 10 indexed citations
15.
Dai, Hanren, Zhiqiang Wu, Hejin Jia, et al.. (2020). Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. Journal of Hematology & Oncology. 13(1). 30–30. 227 indexed citations
16.
Tong, Chuan, Yang Liu, Xingyu Ji, et al.. (2020). Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. Blood. 136(14). 1632–1644. 202 indexed citations
17.
Zhang, Wenying, Yang Liu, Yao Wang, et al.. (2018). Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy. Gene Therapy. 25(3). 198–204. 7 indexed citations
18.
Zhang, Wenying, Yang Liu, Yao Wang, et al.. (2017). Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials. Signal Transduction and Targeted Therapy. 2(1). 17054–17054. 16 indexed citations
19.
Wang, Chunmeng, Zhiqiang Wu, Yao Wang, et al.. (2016). Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. Clinical Cancer Research. 23(5). 1156–1166. 261 indexed citations
20.
Wu, Zhiqiang, Chunmeng Wang, Xiaolei Li, et al.. (2015). An LRP16-containing preassembly complex contributes to NF-κB activation induced by DNA double-strand breaks. Nucleic Acids Research. 43(6). 3167–3179. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Reed M. Hawkins Breakdown of academic impact, for papers by Sherry Adkins Breakdown of academic impact, for papers by Jinjuan Wang Breakdown of academic impact, for papers by Oumar Diouf Breakdown of academic impact, for papers by Xiaojun Qian Breakdown of academic impact, for papers by Kathryn M. Cappell Breakdown of academic impact, for papers by Brandon Ballard Breakdown of academic impact, for papers by Nicholas Tschernia Breakdown of academic impact, for papers by Yongxian Hu Breakdown of academic impact, for papers by Maria‐Luisa Schubert
Rankless by CCL
2026